Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEPIn study of early secukinumab versus narrow-band UVB for new-onset moderate to severe plaque psoriasis
NL-OMON43019Phase 4Withdrawn
- Sponsor
- TFS HealthScience
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of secukinumab in plaque psoriasis (2 arms), sponsored by TFS HealthScience. Primary endpoint: PASI 90 response at Week 52. Planned start Nov 2016; status: withdrawn.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON43019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43019.